Cohance Lifesciences quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	422	549	−23.1%
EBITDA	1.2	112	−99.0%
EBITDA margin	0.3%	20.4%	−20.1 pts
Profit before tax	−42.9	62.8	—
Net profit	−45.2	46.4	—
EPS	−₹0.63	₹1.28	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Q1 FY24Jun 2023	Earlier quartersAlpha Plus

Expenses
	422	619	545	556	549	402	307	258	231	220	231	348	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	12.3	−1.8	6.2	15.6	14.2	10.6	15.7	14.1	18.2	14.3	19.8	10.7
	435	617	551	571	563	413	323	272	249	234	251	358
	159	139	197	192	178	70.2	67.0	47.1	38.3	63.5	51.2	79.8
	−38.4	75.5	−37.6	−50.5	−30.2	63.8	−11.4	5.0	25.3	8.9	6.4	21.5
	133	129	119	127	133	89.1	63.3	51.9	45.6	32.8	28.6	28.7
	6.7	9.2	9.1	8.8	10.2	5.8	3.3	1.7	1.6	1.3	0.5	1.1
	49.5	51.2	46.9	44.0	45.1	26.8	20.4	17.0	13.4	12.8	11.9	12.5
	168	177	172	167	156	105	70.5	49.8	41.5	49.4	46.9	50.6
	477	581	505	487	493	361	213	172	166	169	145	194
	1.2	98.7	95.4	121	112	73.6	118	104	79.9	65.1	98.0	167
	−48.4	47.5	48.4	76.9	66.9	46.8	97.4	87.1	66.5	52.4	86.1	154
Profit
	−42.9	36.4	45.5	83.8	70.9	51.6	110	99.5	83.1	65.5	105	164
	0.0	−16.5	−4.9	0.0	−8.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	−42.9	19.9	40.6	83.8	62.8	51.6	110	99.5	83.1	65.5	105	164
	2.2	22.2	12.4	27.0	18.2	3.8	41.6	27.9	20.0	14.7	24.3	41.3
	0.2	−10.6	−0.9	−9.7	−1.8	9.1	−15.2	−10.4	2.3	4.1	1.6	2.0
	2.3	11.6	11.6	17.4	16.4	12.9	26.4	17.5	22.3	18.7	25.8	43.4
	−45.2	8.3	29.0	66.4	46.4	38.7	83.3	82.0	60.8	46.8	79.6	121
	−45.2	8.3	29.0	66.4	46.4	38.7	83.3	82.0	60.8	46.8	79.6	121
	5.8	86.1	7.0	6.0	−0.1	9.9	2.7	−0.1	0.6	−0.8	0.0	0.0
	−39.4	94.4	36.1	72.4	46.3	48.6	86.0	81.9	61.4	45.9	79.6	121
	−24.1	19.6	36.7	74.1	48.9	42.0	82.9	82.2	—	—	—	121
	−21.1	−11.2	−7.7	−7.7	−2.5	−3.3	0.4	−0.2	0.0	—	—	0.0
Per share
	−₹0.63	₹0.51	₹0.96	₹1.94	₹1.28	₹1.65	₹3.26	₹3.23	₹2.39	₹1.84	₹3.13	₹4.74
	−₹0.65	₹0.50	₹0.96	₹1.93	₹1.27	₹1.59	₹3.23	₹3.21	₹2.39	₹1.84	₹3.13	₹4.74
Other comprehensive income — detail
	5.8	86.1	7.0	6.0	−0.1	9.9	—	—	—	—	—	—
	0.2	96.9	−0.2	−0.1	0.1	9.1	−0.1	−0.1	0.0	−1.1	0.0	0.0
	0.1	26.6	−0.1	−0.0	0.0	2.6	—	—	—	—	—	—
	—	—	—	—	—	—	−0.0	−0.0	0.0	−0.3	0.0	0.0
	7.6	14.3	8.3	3.9	−0.1	3.4	2.8	0.0	0.6	—	—	—
	2.0	−1.4	1.1	−2.2	0.0	0.0	—	—	—	—	—	—
	−18.3	102	42.9	77.1	48.8	51.3	85.6	82.2	—	—	—	121
	−21.1	−7.5	−6.8	−4.7	−2.5	−2.7	0.4	−0.2	—	—	—	0.0
Per share — as-filed variants
	−₹0.63	₹0.51	₹0.96	₹1.94	₹1.28	₹1.65	₹3.26	₹3.23	₹2.39	₹1.84	₹3.13	₹4.74
	−₹0.65	₹0.50	₹0.96	₹1.93	₹1.27	₹1.59	₹3.23	₹3.21	₹2.39	₹1.84	₹3.13	₹4.74
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	302	405	386	414	401	268	252	206	167	147	173	246
	71.5%	65.4%	70.8%	74.6%	73.0%	66.7%	81.9%	79.8%	72.4%	67.0%	75.1%	70.9%
Adjusted (ex-exceptional items) — derived
	−42.9	36.4	45.5	83.8	70.9	51.6	110	99.5	83.1	65.5	105	164
	0.0	−16.5	−4.9	0.0	−8.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	−45.2	15.2	32.5	66.4	52.4	38.7	83.3	82.0	60.8	46.8	79.6	121
	−₹0.63	₹0.93	₹1.07	₹1.94	₹1.45	₹1.65	₹3.26	₹3.23	₹2.39	₹1.84	₹3.13	₹4.74

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

COHANCE₹481.35

Cohance Lifesciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDIVISLAB SYNGENE ASTERDM LALPATHLAB NATCOPHARM WOCKPHARMA NEULANDLAB NHMcap ₹18,416 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q1 FY24 30/06/2023	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	347.6	231.1	219.8	230.7	257.7	307.2	402.0	549.3	555.6	544.6	619.1	422.3
Other Income	10.7	19.8	14.3	18.2	14.1	15.7	10.6	14.2	15.6	6.2	-1.8	12.3
Total Income	358.2	250.9	234.2	248.8	271.8	322.9	412.6	563.5	571.2	550.7	617.3	434.5
Expenses
+ Cost of Materials Consumed	79.8	51.2	63.5	38.3	47.1	67.0	70.2	178.3	191.6	196.5	139.0	158.7
+ Changes in Inventories	21.5	6.4	8.9	25.3	5.0	-11.4	63.8	-30.2	-50.5	-37.6	75.5	-38.4
+ Employee Benefit Expense	28.7	28.6	32.8	45.6	51.9	63.3	89.1	133.3	126.7	118.7	129.0	133.0
+ Finance Costs	1.1	0.5	1.3	1.6	1.7	3.3	5.8	10.2	8.8	9.1	9.2	6.7
+ Depreciation & Amortisation	12.5	11.9	12.8	13.4	17.0	20.4	26.8	45.1	44.0	46.9	51.2	49.5
+ Other Expenses	50.6	46.9	49.4	41.5	49.8	70.5	105.4	155.8	166.8	171.6	177.0	167.9
Total Expenses	194.3	145.5	168.7	165.8	172.3	213.1	361.0	492.6	487.4	505.3	580.9	477.4
EBITDA	167.0	98.0	65.1	79.9	104.0	117.7	73.6	112.0	121.0	95.4	98.7	1.2
EBIT	154.4	86.1	52.4	66.5	87.1	97.4	46.8	66.9	76.9	48.4	47.5	-48.4
Profit
PBT before Exceptional Items	163.9	105.4	65.5	83.1	99.5	109.7	51.6	70.9	83.8	45.5	36.4	-42.9
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.1	0.0	-4.9	-16.5	0.0
Pretax Income	163.9	105.4	65.5	83.1	99.5	109.7	51.6	62.8	83.8	40.6	19.9	-42.9
+ Current Tax	41.3	24.3	14.7	20.0	27.9	41.6	3.8	18.2	27.0	12.4	22.2	2.2
+ Deferred Tax	2.0	1.6	4.1	2.3	-10.4	-15.2	9.1	-1.8	-9.7	-0.9	-10.6	0.2
Tax Expense	43.4	25.8	18.7	22.3	17.5	26.4	12.9	16.4	17.4	11.6	11.6	2.3
Net Income	120.6	79.6	46.8	60.8	82.0	83.3	38.7	46.4	66.4	29.0	8.3	-45.2
+ Net Income — Continuing Ops	120.6	79.6	46.8	60.8	82.0	83.3	38.7	46.4	66.4	29.0	8.3	-45.2
+ Other Comprehensive Income	0.0	0.0	-0.8	0.6	-0.1	2.7	9.9	-0.1	6.0	7.0	86.1	5.8
Total Comprehensive Income	120.6	79.6	45.9	61.4	81.9	86.0	48.6	46.3	72.4	36.1	94.4	-39.4
Net Income to Common	120.6	—	—	—	82.2	82.9	42.0	48.9	74.1	36.7	19.6	-24.1
Minority Interest	0.0	—	—	0.0	-0.2	0.4	-3.3	-2.5	-7.7	-7.7	-11.2	-21.1
Per Share
Basic EPS	4.74	3.13	1.84	2.39	3.23	3.26	1.65	1.28	1.94	0.96	0.51	-0.63
Diluted EPS	4.74	3.13	1.84	2.39	3.21	3.23	1.59	1.27	1.93	0.96	0.50	-0.65
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	9.9	-0.1	6.0	7.0	86.1	5.8
+ Items NOT to be Reclassified to P&L	0.0	0.0	-1.1	0.0	-0.1	-0.1	9.1	0.1	-0.1	-0.2	96.9	0.2
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	2.6	0.0	-0.0	-0.1	26.6	0.1
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.0	-0.3	0.0	-0.0	-0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	—	—	0.6	0.0	2.8	3.4	-0.1	3.9	8.3	14.3	7.6
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.0	0.0	-2.2	1.1	-1.4	2.0
Comprehensive Income — Owners of Parent	120.6	—	—	—	82.2	85.6	51.3	48.8	77.1	42.9	101.9	-18.3
Comprehensive Income — Non-controlling Interests	0.0	—	—	—	-0.2	0.4	-2.7	-2.5	-4.7	-6.8	-7.5	-21.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	4.74	3.13	1.84	2.39	3.23	3.26	1.65	1.28	1.94	0.96	0.51	-0.63
Diluted EPS — Continuing Operations	4.74	3.13	1.84	2.39	3.21	3.23	1.59	1.27	1.93	0.96	0.50	-0.65
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	246.3	173.5	147.4	167.1	205.7	251.5	268.0	401.2	414.4	385.6	404.7	302.0
Gross Margin %	70.86	75.07	67.05	72.43	79.80	81.89	66.67	73.03	74.60	70.82	65.36	71.52
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	163.9	105.4	65.5	83.1	99.5	109.7	51.6	70.9	83.8	45.5	36.4	-42.9
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.1	0.0	-4.9	-16.5	0.0
Net Income Adj (tax-effected)	120.6	79.6	46.8	60.8	82.0	83.3	38.7	52.4	66.4	32.5	15.2	-45.2
EPS Adj	4.74	3.13	1.84	2.39	3.23	3.26	1.65	1.45	1.94	1.07	0.93	-0.63
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	25.5	25.5	25.5	—	25.5	25.5	25.5	38.3	38.3	38.3	38.3	38.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Cohance Lifesciences Q2 FY27 results date

Cohance Lifesciences (NSE: COHANCE) will announce its Q2 FY27 results (July–September 2026) on Friday, 6 November 2026, according to the board-meeting notice it filed on 26 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net loss attributable to shareholders was ₹24.1 crore, against a profit of ₹48.9 crore in Q1 FY26 and against a profit of ₹19.6 crore in Q4 FY26. Revenue from operations was ₹422 crore, down 23.1% year on year and down 31.8% from the previous quarter.

Board-meeting notice filed: 26 October 2026
Q2 FY26 results (a year earlier): 12 November 2025
Q1 FY27 results (the latest): 5 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 6 November 2026Friday · notice filed 26 Oct
Q1 FY27 net loss: −₹24.1 Crprofit ₹48.9 Cr in Q1 FY26profit ₹19.6 Cr in Q4 FY26
Q1 FY27 revenue: ₹422 Cr−23.1% vs Q1 FY26−31.8% vs Q4 FY26
Q1 FY27 operating margin: −11.5%−23.6 pts vs Q1 FY26−19.1 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹74.1 CrRevenue ₹556 Cr
Q1 FY27 EPS (basic): −₹0.63

Questions

When will Cohance Lifesciences announce its Q2 FY27 results?

On 6 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 26 October 2026). Last year it reported Q2 FY26 on 12 November 2025.

What will Cohance Lifesciences' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹74.1 crore and revenue from operations ₹556 crore. The latest quarter, Q1 FY27, had a net loss of ₹24.1 crore and revenue of ₹422 crore.

What was Cohance Lifesciences' revenue in FY26?

Revenue from operations was ₹2,269 crore in FY26 (April 2025–March 2026), up 89.4% from ₹1,198 crore in FY25. It was ₹1,051 crore in FY24 and ₹1,340 crore in FY23: up 69.3% over three years, 19.2% a year on average.

What were Cohance Lifesciences' Q1 FY27 results?

Consolidated net loss attributable to shareholders was ₹24.1 crore, against a profit of ₹48.9 crore in Q1 FY26 and against a profit of ₹19.6 crore in Q4 FY26. Revenue from operations was ₹422 crore, down 23.1% year on year and down 31.8% from the previous quarter.

How has Cohance Lifesciences' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: a profit of ₹74.1 crore in Q2 FY26, a profit of ₹36.7 crore in Q3 FY26, a profit of ₹19.6 crore in Q4 FY26 and a loss of ₹24.1 crore in Q1 FY27. That is a combined profit of ₹106 crore over the four quarters, down 58.5% from ₹256 crore in the four quarters before. Revenue from operations: ₹556 crore, ₹545 crore, ₹619 crore and ₹422 crore.

What was Cohance Lifesciences' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹179 crore in FY26 (April 2025–March 2026), down 33.1% from ₹268 crore in FY25. It was ₹300 crore in FY24 and ₹411 crore in FY23: down 56.4% over three years, an average fall of 24.2% a year.

Where do these Cohance Lifesciences figures come from?

From Cohance Lifesciences' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.